RMOC Buprenorphine Long-acting Injection Guidance: Consultation running until 13/11/2020

Draft guidance has been produced on Buprenorphine long-acting injection: considerations for opioid substitution treatment use in community settings and secure environments in England, on behalf of the RMOC system. The guidance is intended for use by substance misuse service providers (SMSP) in all settings, commissioners, community pharmacies and acute Trusts in England. For this guidance, SMSPs should be interpreted as providers within community and Health and Justice settings (such as prisons, immigration removal centres, children and young people secure estates). The guidance includes the following:

  • Commencing treatment
  • Practical considerations in different care settings
  • Transfer of care
  • Clinical scenarios
  • Recommendations

This guidance has been developed with support from the NEL Commissioning Support Unit, and was developed by a range of stakeholders from various sectors in England with expertise in substance misuse.

A version 1 Buprenorphine Guidance document was presented and discussed at the RMOC South September 2020 meeting. Following discussion and comments received from RMOC South members the document was further amended to produce the attached v2 document.

RMOC South is now inviting comments on the content of the attached draft RMOC Buprenorphine guidance v2 document. Any comments should be returned (in the attached matrix) to rmoc.south@nhs.net no later than 5pm on Friday 13th November 2020.

Comments will be collated by the South West Medicines Information Service (which provides SPS professional support to RMOC South).

Attachments